"Vigilante" <we.ride@night.now> wrote in message

SOUTH SAN FRANCISCO, Calif., Feb. 14

/PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced
that the highly pathogenic isolate of HIV recently identified in a New York
City resident was characterized at ViroLogic using its PhenoSense(TM),
GeneSeq(TM), and Entry Assays to assess resistance to all currently
available antiretroviral drugs. The isolate was sent to ViroLogic for more
extensive testing after initial evaluation at the Aaron Diamond AIDS
Research Center (ADARC) in New York suggested that the recently transmitted
virus was resistant to three of the four classes of standard antiretroviral
therapy. ViroLogic's analysis confirmed the data from ADARC, and
importantly, revealed therapeutic options that informed the selection of a
drug regimen for the patient.

Additional testing was performed using several newer assays developed at
Virologic. The Entry Assay demonstrated that the virus was susceptible to
enfuvirtide (Fuzeon(R)), the only commercially available entry inhibitor
drug. The analysis at ViroLogic also identified the cellular receptors that
this virus uses to enter CD4 cells, the targets of viral infection. The test
results indicate that the virus uses a receptor that has been linked to
accelerated immune destruction and rapid progression to clinical AIDS.
Viruses with significant resistance often replicate less well than wild-type
viruses. In this case however, the ViroLogic Replication Capacity (RC) assay
indicated that virus replication was comparable to most wild-type strains.
Replication Capacity is the focus of intensive study at ViroLogic and
preliminary data indicate that viruses with high RC values are associated
with more rapid immunosuppression.

"This episode serves as a sobering reminder of the potential danger of
transmitted resistant viruses," said David D. Ho, M.D., Scientific Director
and Chief Executive Officer of ADARC in New York and a Professor at The
Rockefeller University. "This is an interesting case because it has features
that we often see, although not typically in the same virus. While we see
triple-class resistance fairly commonly in patients with a long history of
antiretroviral drug experience, this case is noteworthy in that a single
virus harbors triple-class resistance, a high RC, and CXCR4 receptor tropism
in the setting of recent infection. The value of having access to
comprehensive drug resistance testing technologies helped to clarify this
patient's best treatment options."

"While the receptor tropism and RC of this virus suggest possible
explanations for the rapid pace of disease progression in this patient,
additional clinical tests regarding the individual patient's genetic make-up
need to be conducted and are underway. Nonetheless, this appears to be a
virus that is resistant to most antiretroviral drugs, replicates
efficiently, and has led to the rapid onset of AIDS in this patient,"
continued Dr. Ho.

"This case reinforces the importance of resistance testing in the management
of HIV patients, including those individuals who have not received prior
antiretroviral treatment," said Michael Bates, M.D., Vice President of
Clinical Research at ViroLogic. "At ViroLogic, we're focused on
understanding how to use parameters like resistance, RC and tropism more
effectively in patient management. We continue to define and broaden the
clinical utility of ViroLogic's technology, improving the clinician's
ability to optimize the management of antiretroviral therapy for their
patients, and assisting our pharmaceutical colleagues in developing novel
drugs to treat HIV infection."

ViroLogic's drug resistance test PhenoSense GT(TM) combines phenotypic and
genotypic testing into one assay that is performed using a single patient
sample, and is reported on a single form. This combination assay was
developed to provide physicians with a more comprehensive look at an
individual's drug susceptibility profile.

Understanding the clinical utility of Replication Capacity in the management
of HIV-infected patients is currently the subject of a $1.5M grant awarded
to ViroLogic by the National Institutes of Health. The Tropism Assay is
currently being utilized in multiple pharmaceutical sponsored phase 2 and
phase 3 clinical development programs designed to evaluate the efficacy and
safety of inhibitors that block the ability of HIV to infect new cells.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and
improve treatment of serious infectious diseases and cancer. The Company's
products are designed to help doctors optimize treatment regimens for their
patients that lead to better outcomes and reduced costs. The Company's
technology is also being used by numerous biopharmaceutical companies to
develop new and improved antiviral therapeutics and vaccines as well as
targeted cancer therapeutics. More information about the Company and its
technology can be found on its web site at www.virologic.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, including
statements regarding operating results, the future role of ViroLogic's
technology in the management of HIV-infected patients. These forward-looking
statements are subject to risks and uncertainties and other factors, which
may cause actual results to differ materially from the anticipated results
or other expectations expressed in such forward-looking statements. These
risks and uncertainties include, but are not limited to, risks and
uncertainties relating to the performance of our products; our ability to
successfully conduct clinical studies and the results obtained from those
studies; whether larger confirmatory clinical studies will confirm the
results of initial studies; our ability to establish reliable, high-volume
operations at commercially reasonable costs; expected reliance on a few
customers for the majority of our revenues; actual market acceptance of our
products and adoption of our technological approach and products by
pharmaceutical and biotechnology companies; our estimate of the size of our
markets; our estimates of the levels of demand for our products; the timing
and ultimate size of pharmaceutical company clinical trials; whether payors
will authorize reimbursement for its products; whether the FDA or any other
agency will decide to regulate ViroLogic's products or services; whether the
Company will encounter problems or delays in automating its processes;
whether intellectual property underlying the Company's PhenoSense technology
is adequate; whether we may be deemed to infringe on the intellectual
property of others and whether licenses to third party technology will be
available; whether ViroLogic is able to build brand loyalty and expand
revenues; and whether ViroLogic will be able to raise sufficient capital
when required. For a discussion of other factors that may cause ViroLogic's
actual events to differ from those projected, please refer to the Company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q,
as well as other subsequent filings with the Securities and Exchange
Commission.

SOURCE ViroLogic, Inc. 02/14/2005
CONTACT: Alfred Merriweather, Vice President and CFO of ViroLogic, Inc.,
+1-650-635-1100; or Daryl Messinger of WeissComm Partners, +1-415-999-2361,
or daryl@weisscommpartners.com, for ViroLogic, Inc.
Web site: www.virologic.com